<DOC>
	<DOCNO>NCT01598558</DOCNO>
	<brief_summary>Rituximab antibody target CD20 antigen find primarily B-cells . Therefore , image agent target CD20 expression may provide accurate evaluation extent disease response therapy current standard care , F-18 FDG PET/CT . The main purpose study investigate new PET/CT imaging probe detection follow lymphoma . Following 3 aim study : ) Phase I test lymphoma patient Cu-64 label Rituxan define normal tracer biodistribution , stability , pharmacokinetics radiation dosimetry ; b ) comparison Cu-64 Rituxan F-18 FDG PET/CT lymphoma patient ; c ) evaluation change uptake Cu-64 Rituxan response rituximab-based treatment CD20-positive B-cell NHL</brief_summary>
	<brief_title>Assessing Response Treatment Non-Hodgkin 's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients must diagnosis CD20positive Bcell NHL stag 18F FDG PET/CT prior 64CuDOTARituximab PET/CT Patients must understand voluntarily sign Informed Consent form content fully explain Patients must schedule rituximabbased therapy Patients must older 18yearold Patients complete PET/CT scan Pregnant woman Patients participate research protocol exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>